Citations

Clear

9 citation(s) found for "Sidharth, M".

Novel synbiotic yoghurt restores ketogenic diet responsiveness and reduces Alzheimer’s disease pathology in 3xTg-AD mice
James, Adewale, Miller, Brandi, Mishra, Sidharth, Prajapati, Santosh, Chaudhari, Diptaraj, Maleki, Sima , Kumar, Vivek, Adil, Noorul Ain, Omo-erigbe, Christabel, Tangudu, Divyani, Goltz, Dayna, Neth, Bryan, Craft, Suzanne, Jain, Shalini, Yadav, Hariom, Neth, Bryan J. , Mishra, Sidharth P. , Neth, Byran J. , Miller, Brandi C. , Chaudhari, Diptaraj , Goltz, Dayna , Craft, Suzanne , Jain, Shalini, Yadav, Hariom

Mayo Clinic

Physiology | May 12, 2026 | Volume: 41 | Issue: S1 | Pages: No page available

10.1152/physiol.2026.41.s1.2297683 Get It

Alzheimer’s disease (AD) is characterized by profound metabolic dysfunction and disturbances in gut–brain axis signaling. Ketogenic diet (KD) has demonstrated metabolic and cognitive benefits in both preclinical and clinical studies. However, factors that determine individual responsiveness or non-responsiveness to KD interventions remain poorly understood. Emerging evidence suggests that gut microbiome composition plays a critical role in modulating these factors. This study examined how KD responsiveness, determined by fecal microbiota transplantation (FMT) derived from human KD responders (RES) or non-responders (nRES)- influences cognition, gut barrier function, neuroinflammation, and microbial structure in 3xTg-AD mice. We further evaluated whether supplementing KD with a novel Synbiotic Yogurt (SY) formulated by our team could augment or restore responsiveness. We hypothesized that RES microbiota would confer superior KD-driven benefits and that KD-SY would synergistically improve metabolic and neurobiological outcomes, particularly among nRES recipients. Adult 3xTg-AD mice were antibiotic-cleansed and randomized to receive Control-, RES-, or nRES – FMT, while maintained on KD for four weeks. A second cohort received KD supplemented with SY or non-fat milk along with RES- or nRES-FMT. Behavioral tests, gut permeability assay, serum inflammatory markers, brain amyloid beta (Aβ), intestinal morphology, gene expression, and 16S rRNA microbial profiling were measured. RES-FMT recipients showed early improvements in spatial memory (Y-maze and novel object recognition) and consistently lower Aβ accumulation in cortex and hippocampus. They also showed higher synaptophysin and IL-10 expression. In contrast, nRES-FMT mice exhibited distinct microbiome clustering, lower microbial diversity, enrichment of Proteobacteria, and impaired gut barrier function relative to RES-FMT recipients. Functionally, specific taxa like Enterococcus, Enterobacter, and Paenibacillus were associated with greater vulnerability to AD-related pathology, while Akkermansia, Bifidobacterium, and Muribaculum were linked with lower vulnerability. SY supplementation improved metabolic and gut barrier indices across groups characterized by increased circulating ketone levels, lowered fasting glucose and glucose-ketone index, and decreased gut permeability. nRES-SY mice showed the strongest gains in recognition memory and reductions in brain Aβ1–42 burden. SY increased expression of barrier- and inflammation-modulating genes, including occludin, APLP2, and IL-10. Microbiome analysis demonstrated higher microbial diversity and enrichment of beneficial genera such as Paralactobacillus, Eubacterium, and Muribaculum. These findings show that KD responsiveness is strongly determined by gut microbiota composition and that SY supplementation can enhance or rescue metabolic, cognitive, and microbial outcomes, particularly in nonresponders. This supports a precision-microbiome strategy combining metabolic and Synbiotic interventions to improve gut–brain axis function in AD. This abstract was presented at the American Physiology Summit 2026 and is only available in HTML format. There is no downloadable file or PDF version. The Physiology editorial board was not involved in the peer review process.
Artificial intelligence for predicting paediatric acute kidney injury: a systematic review and meta-analysis
Raina, Rupesh, Shirode, Parth , Shah, Raghav , Chepyala, Aanya, Tibrewal, Abhishek, Sethi, Sidharth Kumar, Cheungpasitporn, Wisit, Sethi, Sidharth Kumar , Sethi, Sidharth Kumar , Cheungpasitporn, Wisit , Raina, Rupesh , Cheungpasitporn, Wisit

Mayo Clinic

Clinical Kidney Journal | February 28, 2026 | Volume: 19 | Issue: 5 | Pages: No page available

10.1093/ckj/sfag063 | PMID 42079462 Get It

ABSTRACT Background Acute kidney injury (AKI) in hospitalised children is a major complication associated with significant morbidity and mortality. The integration of artificial intelligence (AI)/machine learning (ML) models may enable early detection and risk stratification. This systematic review evaluates the performance of AI/ML models for predicting paediatric AKI across clinical settings. Methods We systematically searched PubMed, Embase, and Web of Science for studies applying AI/ML models to predict AKI in paediatric populations. Studies reporting performance metrics such as the area under the curve (AUC), sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), accuracy, and F1 score were included. Results Among 470 records identified, 11 studies met the inclusion criteria, with 14 AI/ML models used. The overall sample size included 33 949 paediatric patients with an AKI proportion of 12.5%. Meta-analyses of the AUC were conducted on neural network, gradient boosting, and logistic regression. Gradient boosting had the highest pooled AUC of 0.873 (95% confidence interval 0.836–0.909). Random forest demonstrated the highest median sensitivity (0.821), specificity (0.942), PPV (0.860), NPV (0.935), and accuracy (0.821); however, these metrics could not be pooled due to inconsistent reporting and limited validation. Conclusion Gradient boosting, random forest, and logistic regression demonstrated reasonable predictive performance for paediatric AKI prediction within specific clinical contexts. However, small sample size, heterogeneity, lack of testing/validation cohorts, insufficient data, and inconsistent patient populations and AKI diagnostic criteria restrict generalisability.
Symposia Report of The Annual Biological Sciences Section Meeting of the Gerontological Society of America 2023, Tampa, Florida
Rogina, Blanka , Anderson, Rozalyn M. , Curan, Sean, Yousefzadeh, Matthew J. , Ghosh, Bhaswati, Duque, Gustavo , Howlett, Susan E. , Austad, Steven N. , Korfhage, Justin , Christensen, Kaare , Carey, James R. , Bell, Justice, Gomes, Ana P. , Dixit, Vishwa Deep , Sen, Payel , Imai, Shin‐ichiro , Valdez, Gregorio , Orr, Miranda E. , Jones, Leanne , Castillo-Azofeida, David, Bonaguidi, Michael A. , Suh, Yousin , Duncan, Francesca E. , C, Weigler G Perry, Burkewitz, Kristopher , Zhou, Kai , Bouhrara, Mustapha , Kolind, Shannon , Dean, Doug, Pálovics, Róbert , Niedernhofer, Laura J. , Fan, Rong , Bueckle, Andreas , Kapahi, Pankaj , Jiang, Nisi , Diaz, Jose , Mishra, Sidharth P. , Ralmundo, Nuno, Banarjee, Reema , Allsopp, Richard , Curran, Sean P. , Anderson, Rozalyn M , Curran, Sean P , Yousefzadeh, Matthew J , Duque, Gustavo , Howlett, Susan , Austad, Steven , Demuth, Ilja , Gerstorf, Denis , Abadir, Peter , Christensen, Kaare , Palmer, Allyson, Basisty, Nathan , de Cabo, Rafael , Sen, Payel , Baur, Joseph A , Duncan, Francesca E , Benjamini, Dan , Walker, Keenan A , Dean, Douglas C , Gladyshev, Vadim N , Fan, Rong , Sato, Shogo , Jiang, Nisi , Ashiqueali, Sarah A., Allsopp, Richard , Niedernhofer, Laura J , Kollind, Shannon H , LeBrasseur, Nathan K. , Lombard, David B. , Alberts, Susan C. , Campos, Fernando A. , Palavicini, Juan Pablo , Palmer, Allyson K. , Basisty, Nathan , Cabo, Rafael de , Baur, Joseph A. , Li, Xiaoling , Pletcher, Scott D. , Andersen, Julie Kay , Jones, Leanne, Suh, Yousin , Murray, Anna , Wang, Meng C., Henne, W. Mike , Walker, Keenan A. , Reiter, David A. , Gorbunova, Vera , Gladyshev, Vadim N. , Hurley, Jennifer , Esser, Karyn A. , Ashiqueali, Sarah , Reynolds, Lindsay M. , Zhang, Bohan , Sebastiani, Paola , Monti, Stefano , Schork, Nicholas J. , Rappaport, Noa

Mayo Clinic

The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences | February 11, 2025 | Volume: 80 | Issue: 5 | Pages: No page available

10.1093/gerona/glaf026 | PMID 39932386 Get It

Abstract The aging process is universal, and it is characterized by a progressive deterioration and decrease in physiological function leading to decline on the organismal level. Nevertheless, a number of genetic and nongenetic interventions have been described, which successfully extend healthspan and lifespan in different species. Furthermore, a number of clinical trials have been evaluating the feasibility of different interventions to promote human health. The goal of the annual Biological Sciences Section of the Gerontological Society of America meeting was to share current knowledge of different topics in aging research and provide a vision of the future of aging research. The meeting gathered international experts in diverse areas of aging research including basic biology, demography, and clinical and translational studies. Specific topics included metabolism, inflammaging, epigenetic clocks, frailty, senescence, neuroscience, stem cells, reproductive aging, inter-organelle crosstalk, comparative transcriptomics of longevity, circadian clock, metabolomics, and biodemography.
Point-of-care ultrasound training in nephrology: a position statement by the International Alliance for POCUS in Nephrology
Koratala, Abhilash , Argaiz, Eduardo R. , Anwar, Siddiq , Beaubien‐Souligny, William , Bhasin, Bhavna , Diniz, Hugo , Gallardo, Marco Vaca , Torres, Fredzzia Graterol, Hanko, Jennifer , Jaberi, Aala, Kazory, Amir , Raina, Rupesh, Villavicencio-Cerón, Vanessa, Beaubien-Souligny, William , Husain-Syed, Faeq , Sethi, Sidharth Kumar , Koratala, Abhilash , Romero‐González, Gregorio , Reisinger, Nathaniel C. , Husain‐Syed, Faeq , Raina, Rupesh , Ronco, Claudio , Salgado, Octavio J. , Villavicencio-Cerón, Vanessa, Yadla, Manjusha , Bastos, Marcus Gomes

Mayo Clinic

Clinical Kidney Journal | August 14, 2024 | Volume: 17 | Issue: 11 | Pages: No page available

10.1093/ckj/sfae245 | PMID 39502372 Get It

ABSTRACT Point-of-care ultrasonography (POCUS) has rapidly evolved from a niche technology to an indispensable tool across medical specialties, including nephrology. This evolution is driven by advancements in technology and the visionary efforts of clinicians in emergency medicine and beyond. Recognizing its potential, medical schools are increasingly integrating POCUS into training curricula, emphasizing its role in enhancing diagnostic accuracy and patient care. Despite these advancements, barriers such as limited faculty expertise and ‘lack of’ standardized guidelines hinder widespread adoption and regulation. The International Alliance for POCUS in Nephrology (IAPN), through this position statement, aims to guide nephrologists in harnessing the diagnostic power of POCUS responsibly and effectively. By outlining core competencies, recommending training modalities and advocating for robust quality assurance measures, we envision a future where POCUS enhances nephrology practice globally, ensuring optimal patient outcomes through informed, evidence-based decision-making. International collaboration and education are essential to overcome current challenges and realize the full potential of POCUS in nephrology and beyond.
The effects of COVID‐19 on pediatric and adult solid organ transplant recipients and the emergence of telehealth
Shah, Raghav , Marks, Stephen D. , Johnson, Jonathan N. , Nied, Matthew, Bhatt, Girish Chandra , Bonham, Clark A. , Datla, Nithin, Sethi, Sidharth Kumar , Shah, Raghav , Johnson, Jonathan , Sethi, Sidharth Kumar , Raina, Rupesh , Bartosh, Sharon

Mayo Clinic

Pediatric Transplantation | March 7, 2023 | Volume: 27 | Issue: 4 | Pages: No page available

10.1111/petr.14490 | PMID 36879358 Get It

AbstractBackgroundThe SARS‐CoV‐2 pandemic and corresponding acute respiratory syndrome have affected all populations and led to millions of deaths worldwide. The pandemic disproportionately affected immunocompromised and immunosuppressed adult patients who had received solid organ transplants (SOTs). With the onset of the pandemic, transplant societies across the world recommended reducing SOT activities to avoid exposing immunosuppressed recipients. Due to the risk of COVID‐19‐related outcomes, SOT providers adapted the way they deliver care to their patients, leading to a reliance on telehealth. Telehealth has helped organ transplant programs continue treatment regimens while protecting patients and physicians from COVID‐19 transmission. This review highlights the adverse effects of COVID‐19 on transplant activities and summarizes the increased role of telehealth in the management of solid organ transplant recipients (SOTRs) in both pediatric and adult populations.MethodsA comprehensive systematic review and meta‐analysis were conducted to accentuate the outcomes of COVID‐19 and analyze the efficacy of telehealth on transplant activities. This in‐depth examination summarizes extensive data on the clinical detriments of COVID‐19 in transplant recipients, advantages, disadvantages, patient/physician perspectives, and effectiveness in transplant treatment plans via telehealth.ResultsCOVID‐19 has caused an increase in mortality, morbidity, hospitalization, and ICU admission in SOTRs. Telehealth efficacy and benefits to both patients and physicians have increasingly been reported.ConclusionsDeveloping effective systems of telehealth delivery has become a top priority for healthcare providers during the COVID‐19 pandemic. Further research is necessary to validate the effectiveness of telehealth in other settings.
Real-world outcomes associated with the use of the EmboTrap revascularization device for ischemic stroke in the United States
Brinjikji, Waleed , Ikeme, Shelly , Kottenmeier, Emilie , Khaled, Alia , Sidharth, M, Khanna, Rahul , Kottenmeier, Emilie

Mayo Clinic

Journal of NeuroInterventional Surgery | November 8, 2021 | Volume: 14 | Issue: 11 | Pages: 1068-1072

10.1136/neurintsurg-2021-018175 | PMID 34750107 Get It

Background Mechanical thrombectomy (MT) has become the standard of care for the treatment of acute ischemic stroke (AIS). The EmboTrap revascularization device (CERENOVUS, Johnson & Johnson Medical Devices, Irvine, California, USA) has an innovative, dual layer feature designed to facilitate thrombus retrieval. Objective To investigate the real-world clinical and economic outcomes among patients with AIS undergoing MT using the EmboTrap device in the United States (US). Methods Adult patients (≥18 years) who underwent MT for AIS using the EmboTrap device between July 2018 and December 2020 were identified from the Premier Healthcare Database. Patient outcomes included discharge status (including in-hospital mortality), mean length of stay (LOS), intracranial hemorrhage (ICH), mean hospital costs, and 30-day readmissions (all-cause, cardiovascular (CV)-related, and AIS-related). Results A total of 318 patients (mean age 68.5±14.6 years) with AIS treated with the EmboTrap device as the only stent retriever used were identified. Approximately 25% of patients were discharged to home/home health organization, and the in-hospital mortality rate was 10.7%. The rate of ICH was 16.7%. Mean hospital LOS was 9.9±11.3 days, and the mean hospital costs were US$47 367±30 297. The 30-day readmission rate was 9.6% for all-causes, 5.9% for CV-related causes, and 2.6% for AIS-related causes. Conclusions This is the first study in the US to report real-world outcomes sourced by retrospective database analysis among patients with AIS undergoing MT using the EmboTrap device. Further research is needed to better understand performance of the EmboTrap device in real-world settings.
International Dermoscopy Society criteria for non‐neoplastic dermatoses (general dermatology): validation for skin of color through a Delphi expert consensus
Errichetti, Enzo , Ankad, Balachandra S. , Akay, Bengü Nisa , Bakos, Roberto, Bhat, Yasmeen Jabeen , Bosseila, Manal , Cabo, Horacio , Sabban, Emilia N. Cohen, Chatterjee, Manas , Kelati, Awatef , Vinay, Keshavamurthy , Sadek, Ahmed, Swanson, David C. , Tejasvi, Trilokraj , Usatine, Richard P., Daneshpazhooh, M , Jakhar, Deepak , Kaliyadan, Feroze , Kelati, Awatef , Keshavamurthy, Vinay , Swanson, David L, Akay, Bengu Nisa , Jha, Abhijeet Kumar , Sonthalia, Sidharth , Braun, Ralph Peter , Neema, Shekhar , Salerni, Gabriel , Lallas, Aimilios

Mayo Clinic

International Journal of Dermatology | July 3, 2021 | Volume: 61 | Issue: 4 | Pages: 461-471

10.1111/ijd.15729 | PMID 34216025 Get It

AbstractBackgroundThe International Dermoscopy Society (IDS) recently released a set of five basic dermoscopic parameters (vessels, scales, follicular findings, “other structures,” and specific clues) encompassing a total of 31 subitems to standardize the use of dermoscopy in non‐neoplastic dermatoses, yet they have been developed taking into account Caucasian/Asian skin, with consequent possible limitations if used in dark skin.ObjectivesTo validate the abovementioned criteria for the use in dark‐skinned patients (phototypes IV–VI) through an expert consensus.MethodsThe two‐round Delphi method was adopted, with an iterative process consisting of two rounds of email questionnaires. Potential panelists were recruited via e‐mail from all over the world based on their expertise on dermoscopy of non‐neoplastic dermatoses in skin of color.ResultsTwenty‐two panelists took part in the validation process. All of the five originally proposed parameters and subitems reached agreement during the first round, aside from “follicular red dots.” Additionally, during round 1, five new subitems were proposed (perifollicular scales distribution, follicular openings obliteration, broken hairs, eccrine pigmentation, and eccrine ostia obliteration), along with the possibility to change the denomination of parameter 3 (from “follicular findings” to “follicular/eccrine findings”) and split it into two subparameters (“follicular findings” and “eccrine findings”). All such proposals reached agreement during the second round and therefore were included in the final list, for a total of 37 items.ConclusionsAlthough nearly all the dermoscopic criteria originally proposed by the IDS are applicable even to darker phototypes, several additional variables need to be assessed.
Protocadherin 7–Associated Membranous Nephropathy
Sethi, Sanjeev , Morelle, Johann , Charlesworth, M. Cristine , Gross, LouAnn, Negron, Vivian , Buob, David , Chaudhry, Sidharth, Jadoul, Michel , Morelle, Johann , Jadoul, Michel , Madden, Benjamin J. , Dêbiec, Hanna , Charlesworth, M. Cristine , Fervenza, Fernando C. , Ronco, Pierre Marie

Mayo Clinic

Journal of the American Society of Nephrology | April 8, 2021 | Volume: 32 | Issue: 5 | Pages: 1249-1261

10.1681/asn.2020081165 | PMID 33833079 Get It

Significance Statement Membranous nephropathy (MN) results from antibodies targeting an antigen in the glomerular basement membrane (GBM). The target antigens identified so far include PLA2R, THSD7A, NELL1, SEMA3B, and EXT1/EXT2. Using laser microdissection and mass spectrometry analysis, the authors identified a novel protein, protocadherin 7 (PCDH7), that is present in the GBM of a subset of patients with MN who are negative for all of the known antigens associated with MN. PCDH7 shows granular GBM staining and colocalizes with Ig in the GBM. Furthermore, antibodies to PCDH7 were detected in both the serum and kidney biopsy tissue from individuals with PCDH7-associated MN but not from controls. These findings suggest that PCDH7-associated MN defines a distinct type of MN. Background Membranous nephropathy (MN) results from deposition of antigen-antibody complexes along the glomerular basement membrane (GBM). PLA2R, THSD7A, NELL1, and SEMA3B account for 80%–90% of target antigens in MN. Methods We performed laser microdissection and mass spectrometry (MS/MS) in kidney biopsies from 135 individuals with PLA2R-negative MN, and used immunohistochemistry/immunofluorescence and confocal microscopy to confirm the MS/MS finding, detect additional cases, and localize the novel protein. We also performed MS/MS and immunohistochemistry on 116 controls and used immunofluorescence microscopy to screen biopsy samples from two validation cohorts. Western blot and elution studies were performed to detect antibodies in serum and biopsy tissue. Results MS/MS studies detected a unique protein, protocadherin 7 (PCDH7), in glomeruli of ten (5.7%) PLA2R-negative MN cases, which also were negative for PLA2R, THSD7A, EXT1/EXT2, NELL1, and SEMA3B. Spectral counts ranged from six to 24 (average 13.2 [SD 6.6]). MS/MS did not detect PCDH7 in controls (which included 28 PLA2R-positive cases). In all ten PCDH7-positive cases, immunohistochemistry showed bright granular staining along the GBM, which was absent in the remaining cases of PLA2R-negative MN and control cases. Four of 69 (5.8%) cases in the validation cohorts (all of which were negative for PLA2R, THSD7A, EXT1, NELL1, and SEMA3B) were PCDH7-positive MN. Kidney biopsy showed minimal complement deposition in 12 of the 14 PCDH7-associated cases. Confocal microscopy showed colocalization of PCDH7 and IgG along the GBM. Western blot analysis using sera from six patients showed antibodies to nonreduced PCDH7. Elution of IgG from frozen tissue of PCDH7-associated MN showed reactivity against PCDH7. Conclusions MN associated with the protocadherin PCDH7 appears to be a distinct, previously unidentified type of MN.